Nuclear-import Receptors As Gatekeepers of Pathological Phase Transitions in ALS/FTD

Overview

Journal Mol Neurodegener

Publisher Biomed Central

Specialties Molecular Biology
Neurology

Date 2024 Jan 23

PMID 38254150

Authors

Bilal Khalil

Miriam Linsenmeier

Courtney L Smith

James Shorter

Wilfried Rossoll

Affiliations

Soon will be listed here.

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal neurodegenerative disorders on a disease spectrum that are characterized by the cytoplasmic mislocalization and aberrant phase transitions of prion-like RNA-binding proteins (RBPs). The common accumulation of TAR DNA-binding protein-43 (TDP-43), fused in sarcoma (FUS), and other nuclear RBPs in detergent-insoluble aggregates in the cytoplasm of degenerating neurons in ALS/FTD is connected to nuclear pore dysfunction and other defects in the nucleocytoplasmic transport machinery. Recent advances suggest that beyond their canonical role in the nuclear import of protein cargoes, nuclear-import receptors (NIRs) can prevent and reverse aberrant phase transitions of TDP-43, FUS, and related prion-like RBPs and restore their nuclear localization and function. Here, we showcase the NIR family and how they recognize cargo, drive nuclear import, and chaperone prion-like RBPs linked to ALS/FTD. We also discuss the promise of enhancing NIR levels and developing potentiated NIR variants as therapeutic strategies for ALS/FTD and related neurodegenerative proteinopathies.

Citing Articles

Inferring gene regulatory networks of ALS from blood transcriptome profiles.

Pappalardo X, Jansen G, Amaradio M, Costanza J, Umeton R, Guarino F Heliyon. 2024; 10(23):e40696.

PMID: 39687198 PMC: 11648123. DOI: 10.1016/j.heliyon.2024.e40696.

Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson's and other related neurodegenerative diseases.

Riaz Z, Richardson G, Jin H, Zenitsky G, Anantharam V, Kanthasamy A Mol Neurodegener. 2024; 19(1):87.

PMID: 39578912 PMC: 11585115. DOI: 10.1186/s13024-024-00774-0.

Circulating blood circular RNA in Parkinson's Disease; from involvement in pathology to diagnostic tools in at-risk individuals.

Beric A, Sun Y, Sanchez S, Martin C, Powell T, Kumar R NPJ Parkinsons Dis. 2024; 10(1):222.

PMID: 39557914 PMC: 11574145. DOI: 10.1038/s41531-024-00839-3.

NEMF mutations in mice illustrate how Importin-β specific nuclear transport defects recapitulate neurodegenerative disease hallmarks.

Plessis-Belair J, Ravano K, Han E, Janniello A, Molina C, Sher R PLoS Genet. 2024; 20(9):e1011411.

PMID: 39312574 PMC: 11449308. DOI: 10.1371/journal.pgen.1011411.

hnRNPs: roles in neurodevelopment and implication for brain disorders.

Tilliole P, Fix S, Godin J Front Mol Neurosci. 2024; 17:1411639.

PMID: 39086926 PMC: 11288931. DOI: 10.3389/fnmol.2024.1411639.

References

Pool M . Signal recognition particles in chloroplasts, bacteria, yeast and mammals (review). Mol Membr Biol. 2005; 22(1-2):3-15. DOI: 10.1080/09687860400026348. View

Gu J, Wang C, Hu R, Li Y, Zhang S, Sun Y . Hsp70 chaperones TDP-43 in dynamic, liquid-like phase and prevents it from amyloid aggregation. Cell Res. 2021; 31(9):1024-1027. PMC: 8410890. DOI: 10.1038/s41422-021-00526-5. View

McGoldrick P, Lau A, You Z, Durcan T, Robertson J . Loss of C9orf72 perturbs the Ran-GTPase gradient and nucleocytoplasmic transport, generating compositionally diverse Importin β-1 granules. Cell Rep. 2023; 42(3):112134. DOI: 10.1016/j.celrep.2023.112134. View

Guo L, Kim H, Wang H, Monaghan J, Freyermuth F, Sung J . Nuclear-Import Receptors Reverse Aberrant Phase Transitions of RNA-Binding Proteins with Prion-like Domains. Cell. 2018; 173(3):677-692.e20. PMC: 5911940. DOI: 10.1016/j.cell.2018.03.002. View

Kariko K . Developing mRNA for Therapy. Keio J Med. 2022; 71(1):31. DOI: 10.2302/kjm.71-001-ABST. View

Beijer D, Kim H, Guo L, ODonovan K, Mademan I, Deconinck T . Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation. JCI Insight. 2021; 6(14). PMC: 8410042. DOI: 10.1172/jci.insight.148363. View

Suarez-Calvet M, Neumann M, Arzberger T, Abou-Ajram C, Funk E, Hartmann H . Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS. Acta Neuropathol. 2016; 131(4):587-604. DOI: 10.1007/s00401-016-1544-2. View

Davidson Y, Robinson A, Hu Q, Mishra M, Baborie A, Jaros E . Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes. Neuropathol Appl Neurobiol. 2012; 39(2):157-65. PMC: 3479345. DOI: 10.1111/j.1365-2990.2012.01274.x. View

Ritson G, Custer S, Freibaum B, Guinto J, Geffel D, Moore J . TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci. 2010; 30(22):7729-39. PMC: 2890254. DOI: 10.1523/JNEUROSCI.5894-09.2010. View

10.

Couthouis J, Hart M, Shorter J, DeJesus-Hernandez M, Erion R, Oristano R . A yeast functional screen predicts new candidate ALS disease genes. Proc Natl Acad Sci U S A. 2011; 108(52):20881-90. PMC: 3248518. DOI: 10.1073/pnas.1109434108. View

11.

Naganuma T, Nakagawa S, Tanigawa A, Sasaki Y, Goshima N, Hirose T . Alternative 3'-end processing of long noncoding RNA initiates construction of nuclear paraspeckles. EMBO J. 2012; 31(20):4020-34. PMC: 3474925. DOI: 10.1038/emboj.2012.251. View

12.

Patel A, Lee H, Jawerth L, Maharana S, Jahnel M, Hein M . A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell. 2015; 162(5):1066-77. DOI: 10.1016/j.cell.2015.07.047. View

13.

Freibaum B, Lu Y, Lopez-Gonzalez R, Kim N, Almeida S, Lee K . GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015; 525(7567):129-33. PMC: 4631399. DOI: 10.1038/nature14974. View

14.

Petrovic S, Samanta D, Perriches T, Bley C, Thierbach K, Brown B . Architecture of the linker-scaffold in the nuclear pore. Science. 2022; 376(6598):eabm9798. PMC: 9867570. DOI: 10.1126/science.abm9798. View

15.

Weishaupt J, Hyman T, Dikic I . Common Molecular Pathways in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Trends Mol Med. 2016; 22(9):769-783. DOI: 10.1016/j.molmed.2016.07.005. View

16.

Park J, Ryu S, Kim B, Cho H, Park C, Choi H . Disruption of nucleocytoplasmic trafficking as a cellular senescence driver. Exp Mol Med. 2021; 53(6):1092-1108. PMC: 8257587. DOI: 10.1038/s12276-021-00643-6. View

17.

Igaz L, Kwong L, Xu Y, Truax A, Uryu K, Neumann M . Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008; 173(1):182-94. PMC: 2438296. DOI: 10.2353/ajpath.2008.080003. View

18.

Troakes C, Hortobagyi T, Vance C, Al-Sarraj S, Rogelj B, Shaw C . Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS.... Neuropathol Appl Neurobiol. 2012; 39(5):553-61. DOI: 10.1111/j.1365-2990.2012.01300.x. View

19.

Khosravi B, Hartmann H, May S, Mohl C, Ederle H, Michaelsen M . Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD. Hum Mol Genet. 2017; 26(4):790-800. PMC: 5409121. DOI: 10.1093/hmg/ddw432. View

20.

King O, Gitler A, Shorter J . The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012; 1462:61-80. PMC: 3372647. DOI: 10.1016/j.brainres.2012.01.016. View